BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• Press Releases

  uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update

  November 10, 2025

   · 

  16 min read
• Press Releases

  Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

  November 10, 2025

   · 

  26 min read
• Press Releases

  Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

  November 10, 2025

   · 

  17 min read
• Press Releases

  Eight out of 10 infants and newborns in Canada have access to RSV prevention with Beyfortus® this season

  November 10, 2025

   · 

  5 min read
• Press Releases

  Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis

  November 10, 2025

   · 

  15 min read
• Press Releases

  Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

  November 10, 2025

   · 

  7 min read
• Press Releases

  BioVersys BV100 Phase 2b to be Conducted Via Wellcome Funded Trial Network

  November 10, 2025

   · 

  11 min read
• Press Releases

  Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

  November 10, 2025

   · 

  9 min read
• Press Releases

  [Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis

  November 10, 2025

   · 

  9 min read
• Press Releases

  Virion Therapeutics Reports Progress Towards HBV Functional Cure with Sustained and Continued HBsAg Declines up to One Year After a Single VRON-0200 Dose From its Phase 1b Study at AASLD’s The Liver Meeting® 2025

  November 10, 2025

   · 

  5 min read